Puma Biotechnology

PBYI

Market cap $254M

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Puma Biotechnology has been in something of a stasis for years, selling one drug with no new approvals while developing alisertib. The cash position remains strong enough to carry them through key readouts of the ALISCA trials. Two interim readouts guided in 1H 2026 will inform what is next for PBYI, and I think this has a lot of promise.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 5, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 11,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awa.

Puma Biotechnology, Inc. ( PBYI ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Mariann Ohanesian - Senior Director of Investor Relations Alan Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber Roger Storms Maximo F. Nougues - CFO & Principal Accounting Officer Conference Call Participants Marc Frahm - TD Cowen, Research Division Presentation Operator Good afternoon.

Puma Biotechnology beats third-quarter estimates for earnings and revenues and lifts its 2025 outlook on stronger Nerlynx sales.

Puma Biotech (PBYI) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.45 per share a year ago.

LOS ANGELES--(BUSINESS WIRE)--On 11/6/26, Puma Biotechnology issued its financials for Q3-2025 and hosted a conference to discuss operating results.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third quarter of 2025.

There's a small portion of my portfolio I allocate toward companies I'd put in the “higher risk” bucket.

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of one inducement award to a new hire in Sept. 2025, as required by Nasdaq Listing Rule 5635(c)(4).